ECSP099251A - Formulaciones farmacéuticas - Google Patents

Formulaciones farmacéuticas

Info

Publication number
ECSP099251A
ECSP099251A EC2009009251A ECSP099251A ECSP099251A EC SP099251 A ECSP099251 A EC SP099251A EC 2009009251 A EC2009009251 A EC 2009009251A EC SP099251 A ECSP099251 A EC SP099251A EC SP099251 A ECSP099251 A EC SP099251A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
active agent
formulation
release
salt
Prior art date
Application number
EC2009009251A
Other languages
English (en)
Spanish (es)
Inventor
Yi Gao
R Ju Tzuchi
Dennis Y Lee
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Fournier Lab Ireland Ltd filed Critical Abbott Lab
Publication of ECSP099251A publication Critical patent/ECSP099251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2009009251A 2006-10-12 2009-04-13 Formulaciones farmacéuticas ECSP099251A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
ECSP099251A true ECSP099251A (es) 2009-06-30

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009251A ECSP099251A (es) 2006-10-12 2009-04-13 Formulaciones farmacéuticas

Country Status (14)

Country Link
EP (1) EP2081563A1 (enExample)
JP (1) JP2010506855A (enExample)
KR (1) KR20090119959A (enExample)
CN (1) CN101677981A (enExample)
AU (1) AU2007307641A1 (enExample)
CA (1) CA2672686A1 (enExample)
CO (1) CO6160302A2 (enExample)
EA (1) EA200900531A1 (enExample)
EC (1) ECSP099251A (enExample)
IL (1) IL198160A0 (enExample)
MX (1) MX2009003815A (enExample)
SG (1) SG175570A1 (enExample)
WO (1) WO2008046052A1 (enExample)
ZA (1) ZA200902488B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2285357T3 (da) * 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP5114382B2 (ja) * 2005-04-08 2013-01-09 アボット・ラボラトリーズ フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤

Also Published As

Publication number Publication date
SG175570A1 (en) 2011-11-28
WO2008046052A1 (en) 2008-04-17
CN101677981A (zh) 2010-03-24
KR20090119959A (ko) 2009-11-23
JP2010506855A (ja) 2010-03-04
EA200900531A1 (ru) 2009-12-30
MX2009003815A (es) 2009-09-07
CA2672686A1 (en) 2008-04-17
IL198160A0 (en) 2009-12-24
AU2007307641A1 (en) 2008-04-17
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27
CO6160302A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
ES2528924T3 (es) Formulación para el cuidado de heridas
MX2009004439A (es) Composicion de ibuprofeno.
NI201300054A (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
WO2009066146A3 (en) Stable solutions of sparingly soluble actives
ECSP099251A (es) Formulaciones farmacéuticas
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CO6140021A2 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
MX2007011039A (es) Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos.
BR112013006632A2 (pt) composições e sistema de liberação de distribuição de droga aprimorados
ES2563632T3 (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
ECSP078010A (es) Formulación de liberación prolongada de principios activos que presentan una solubilidad dependiente del ph
FR2937867B1 (fr) Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
BRPI0821975B8 (pt) Sistema terapêutico transdérmico (tts) para liberação de substâncias ativas farmacêuticas através da pele, processo para preparação de um sistema terapêutico transdérmico e uso de uma camada polimérica contendo substância ativa
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph
AR070617A1 (es) Formulacion farmaceutica que comprende oxabispidinas/236
BRPI0608083A2 (pt) composição compreendendo ocaperidona